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 Secretion of Recombinant Human fibrinogen by the Murine 
Mammary Gland 
 
Abstract 
 
Transgenic animals secreting individual chains and assembled fibrinogen were produced to 
evaluate the capacity of the mammary gland for maximizing assembly, glycosylation and 
secretion of recombinant human fibrinogen (rhfib). Transgenes were constructed from the 4.1 kbp 
murine Whey Acidic Protein promoter (mWAP) and the three cDNAs coding for the Aα,Bβ and 
γ fibrinogen chains. Transgenic mice secreted fully assembled fibrinogen into milk at 
concentrations between 10 and 200   μg/ml, with total secretion of subunits approaching   700 μ 
g/ml in milk. Partially purified fibrinogen was shown to form a visible and stable clot after 
treatment with human thrombin and factor XIII. The level of assembled fibrinogen was 
proportional to the lowest amount of subunit produced where both the Bβ and γ chains were rate 
limiting. Both the Bβ and γ chains were glycosylated when co-expressed and the degree of 
saccharide maturation was dependent on expression level, with processing preferred for γ chains 
over chains. Also, the subunit complexes Aαγ2, γ2 and the individual subunits Aα, Bβ and γ were 
found as secretion products. When the Bβ was secreted individually, the glycosylation profile of 
the molecule was of a mature complex saccharide indicating recognition of the molecule by the 
glycosylation pathway without association with other fibrinogen chains. To date secretion of Bβ 
chain has been not observed in any cell type, suggesting that the secretion pathway in mammary 
epithelia is less restrictive than that occurring in hepatocytes and other cells previously used to 
study fibrinogen assembly.  
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 1.0 Introduction  
 
Fibrinogen (AαBβγ)2 is a complex plasma glyco-protein that participates in the blood 
coagulation cascade. It is synthesized in the liver as a dimeric molecule that is comprised of two 
subunits linked by three disulfide bonds, each containing three polypeptide chains for a combined 
molecular weight of 340 kDa. The three polypeptides, Aα (66 kDa), Bβ (54 kDa), and γ (48 kDa) 
are linked by disulfide rings to form a coiled spiral of α-helices (Doolittle, 1984). N-linked 
polysaccharides are present on the Bβ and γ chains of both subunits and glycosylations of these 
chains are required for fibrin polymerization by thrombin. Applications for fibrin sealant have 
been developed including use as a hemostatic agent and as a carrier matrix for the delivery of 
drugs and biologics (Greco et al., 1991; Alving et al., 1995; MacPhee et al., 1996a, b; Lasa et al., 
1996). Thus, there is considerable economic incentive to develop recombinant versions of human 
fibrinogen (rhfib), which would be specific-pathogen-free and cost effectively abundant 
(Velander et al., 1996).  
The cDNA sequences coding for each fibrinogen chain have been cloned (Rixon et al., 
1983; Chung et al., 1983a, b), and the synthesis and secretion of fibrinogen have been extensively 
studied in cultured hepatocytes and a variety of transfected cell types (Yu et al., 1984; 
Danishefsky et al., 1990, Roy et al., 1990, 1991; Hartwig & Danishefsky, 1991; Huang et al., 
1993, 1996: Zhang & Redman, 1996). Pulse chase experiments in hepatocytes have determined 
that the rates of new chain synthesis for each peptide are identical (Roy et al., 1994), and newly 
synthesized Bβ-chain associates rapidly with already present intracellular pools of Aα and γ 
chains, suggesting β-chain  incorporation in chain assembly is the rate limiting step in fibrinogen 
production (Yu et al., 1984). Regulation of the intracellular pools of free chains appears to be 
modulated by retrotranslocation, where association of the free chains with translocon component 
Sec61b leads to their eventual degradation in the proteasome (Hui & Redman, 2001). Secretion 
into cell culture media is not limited to fully assembled fibrinogen, but includes free chains of Aα 
and γ , Aα – γ complex and Aα Bβ  γ half molecules (Hartwig & Danishefsky, 1991; Roy et al., 
1991). In contrast, secretion of significant amounts of Bβ -chain has not been observed by any 
cell type and is thought to be retained and degraded when the other fibrinogen chains are not 
present (Danishefsky et al., 1990).  
Currently, fully assembled fibrinogen has been secreted into the milk of both mice and 
sheep carrying the genomic fibrinogen coding sequences linked to the ovine β lactoglobulin 
(oBLG) milk protein promoter (Prunkard et al., 1996; Cottingham et al., 1997). The 
concentration of fibrinogen subunits in mouse milk, as determined by reduced Western analysis, 
varied from 30 to 2000  μg/ml depending upon the transgenic line studied. It was also reported 
that when all three subunits were expressed in a balanced ratio, 100% of the subunit chains were 
incorporated into fully assembled fibrinogen. The glycosylation status of the Bβ  and γ subunits 
was not reported, but purified rhfib was shown to undergo thrombin induced polymerization and 
γ-chain  cross-linking by Factor XIII.  
The objective of this study was to evaluate the capacity of the mammary gland for 
secreting each separate fibrinogen subunit and to then characterize the maturity of the 
glycosylation. We confirm the assembly of functional fibrinogen using the whey acidic protein 
promoter to direct synthesis of each of the subunit chains and then assess the secretion and 
glycosylation of individual chains, along with the glycosylation state of both the Bβ  and γ 
subunits of secreted assembled fibrinogen. In the context of the normal physiology of the 
mammary epithelial cell as it occurs in a transgenic mouse, we show for the first time that the Bβ  
chain having mature glycosylation can be efficiently secreted by a mammalian cell.  
2.0 Materials and methods  
2.1 Transgene construction  
The 4.1 kbp murine whey acidic protein (mWAP) promoter was obtained by digestion of 
p227.6 (American Red Cross, Rockville, MD) with NotI, KpnI and HindIII. The fragment 
containing the 30 UTR and pUC NotI + vector was obtained by partial digestion of pUCWAP5 
(Virginia Polytechnic Institute and State University, Blacksburg, VA) with NotI and a full 
digestion with KpnI. The resulting fragments were then ligated to make the cassette vector 
pUCWAP6. After size and restriction site verification (NotI and NotI/ KpnI digest), large scale 
purification was performed. The cDNAs for cloning were obtained from Susan Lord (University 
of North Carolina, Chapel Hill, NC) and end modified by polymerase chain reaction (PCR) to 
produce KpnI sites directly 5’and 3’ of the coding start and stop sequences, respectively. The 
vector pUCWAP6 was linearized with KpnI, combined with each cDNA and ligated. The 
following restriction endonuclease enzymes were used for verifying the cDNA orientation: 
pUCWAP6FibAα1/PstI yielding expected fragments of 2.1, 2.4 and 5.9 kbp;  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Transgene design and Southern analysis of established transgenic lines. The three fibrinogen 
transgenes, WAP6FibAa, WAP6FiBβ and WAP6Fib1 were produced by introducing the cDNA for each 
chain between the 4.1 kbp promoter and 1.6 kbp30UTR elements of mWAP, upper panel. These constructs, 
in turn, were used to produce founder animals through microinjection. Offspring from these founders were 
screened by Southern analysis with one example from each line presented in lower panel. N.T. = non-
transgenic,°C= band produced by endogenous WAP. Bands Aa,Bβ  and γ  are produced by their 
corresponding transgenic constructs.  
 
pUCWAP6FiBβ b1/BamHI yielding fragments of 750 bp and 9.5 kbp; and pUCWAP6Fibc1/PstI 
yielding fragments of 980 bp, 3.2 and 5.8 kbp (Figure 1). After verifying the sequences across the 
promoter/cDNA and cDNA/3’ UTR junctions, plasmids were cut with NotI/PvuI and constructs 
purified by ultracentrifugation through a NaCl step gradient (7.5, 12.5, 17.5, and 20%) by the 
method of Fink (1991). Construct DNA was diluted to 5 μg/ml in microinjection buffer (10 mM 
Tris–HCl, 0.1 mM EDTA) to produce monogenic lines or mixed in equal molar amounts for co-
microinjection at a final concentration of 5 μg/ml.  
2.2 Generation of transgenic animals  
Generation of transgenic mice followed the general method of Hogan et al. (1986) for 
embryo collection and Canseco et al. (1994) for embryo microinjection. Experiments on animals 
in this study were approved by the University Animal Care Committee and followed the National 
Research Council’s guide for the care and use of laboratory animals. Briefly, female CD-1 mice 
approximately 25–29 days of age were superovulated with intraperitoneal injections of 10 IU 
Pregnant Equine Serum Gonadotropin followed by 5 IU human Chorionic Gonadotropin (hCG) 
48 h later and placed with males. Zygotes from mated mice were collected in M2 medium 21 h 
after hCG and microinjected with 1–4 pl of DNA solution at 5  μg/ml. Surviving embryos were 
transferred to oviducts of pseudopregnant females (30–100 embryos per recipient) with the 
number transferred reflective of survivability studies done in culture for each preparation of 
DNA.  
2.3 Identification of transgenic animals  
DNA samples were isolated from murine tail biopsies by the method of Velander et al. 
(1992) and subjected to PCR analysis by general method of Saiki et al. (1989). PCR positive 
animals were further screened by Southern analysis. Southern analysis was performed on 10 lgof 
tail biopsy DNA digested with endonuclease PstI and probed with a radiolabelled [a-
32P]dATPPstI/KpnI promoter fragment. Digestion of trigenic mouse DNA with endonuclease 
PstI, which cuts each construct at the same site in the promoter region but varies the 3’ cut, 
produced fragment sizes of 4.3 kbp for WAP6FiBβ b1, 3.0 kbp for WAP6Fibc1 and 2.2 for 
WAP6FibA1 (Figure 1). The WAP probe hybridized with each fragment identically and also 
hybridized with a 5.0 kbp fragment produced by the endogenous WAP gene. Relative copy 
numbers for each construct within a given line were determined by comparing each lane’s 
internal WAP control (2 copies) to the signal intensity produced for each construct. Signal 
intensity (by volume determination) from autoradiographic film was performed using a 
densitometer and the corresponding Image Quant software (Molecular Dynamics, Sunnyvale, 
CA).  
 
 
 
2.4 Collection and processing of mouse milk  
Milk from transgenic and control mice was directly collected into 1.7 ml centrifuge tubes 
by vacuum aspiration, with 200 μl of milk removed, added to 200 μl of milk buffer (50 mM Tris 
and 200 mM EDTA, pH 8.5) and frozen at -90 °C. Milk samples were defatted by centrifugation 
at 15,000 x g in a bench top centrifuge for 20 min at 4°C. After skimming, the resulting clarified 
milk (prepared whey) was stored at- 90 °C until analysis.  
 
2.5 Western analysis  
Gel electrophoresis was carried out on polyacrylamide gradient gels from Novex (San 
Diego, CA), 8–16% for reducing conditions and 4–12% for non-reducing conditions using Tris–
glycine buffer (25 mM Tris, 0.1% SDS and 200 mM glycine). Unless otherwise noted, 1 μl of 
prepared whey was loaded per sample and electrophoresis was conducted until the 7.0 kDa 
marker reached the end of the gel or ran off. Gels were transferred to PVDF membranes (BioRad) 
in Towbin buffer (10% methanol, 200 mM glycine, 25 mM Tris, 0.1% SDS) at 4°C, at 200 mA 
overnight using a BioRad Trans-blot cell. Membranes were blocked using TBSTC (20 mM Tris, 
50 mM NaCl, 0.05% Tween 20, 0.5% bovine casein, pH 7.2) for 3 h to overnight with gentle 
agitation. Blots were probed with a primary antibody for 1–3 h at 37 °C with gentle agitation. 
Primary antibodies and the concentrations used were: polyclonal raBβ it anti-Aα-chain (AB784), 
anti-Bβ -chain (AB785), anti-γ-chain  (AB786) from Chemicon International Inc. (Temecula, 
CA) and used at 1:5000; ADI (1:1000), raBβ it polyclonal for all three fibrinogen chains 
(American Diagnostic Inc.); Y18 mAb (1:1000), mouse monoclonal for Aα-chain; Shainoff 
mAb(1:300), mouse monoclonal for Bβ  chain; and NS15 pAb (1:150), raBβ it polyclonal for γ-
chain . The Y18 mAb, Shainoff mAb and NS15 pAb were kindly provided by Susan Lord 
(University of North Carolina; Chapel Hill, NC). After incubation, the blots were rinsed in 
deionized water for 5 min. Horseradish peroxidase conjugated antibodies used include raBβ it 
anti-hfib (Dako A/S, Denmark), goat anti-raBβ it IgG and goat anti-mouse IgG (Sigma A9169, 
and A4416), respectively. After incubation the blots were rinsed three times in deionized water 
and developed according to manufacturer’s instructions for 1–10 min using a metal enhanced 
Diaminobenzidine kit (Pierce, Rockford, IL). Deglycosylation experiments were performed using 
Endoglycosidase-H or PNGase (New England Biolabs, Beverly, MA) with 150 U/mg of protein, 
per manufacturer’s instructions. Samples were separated by electrophoresis and blotted as above 
and probed with either AB785 or AB786 (1:5000) polyclonal raBβ it antibody (Chemicon 
International, Inc.). Hfib standard was provided by the American Red Cross.  
 
2.6 Detection of rhfib by ELISA  
The level of rhfib in the prepared whey samples was determined by polyclonal ELISA. 
Plasma derived hfib was used as a reference standard. Immulon II microtiter plates were coated 
with 5 mg/ml of raBβ it anti-hfib diluted in 0.1 M NaHCO3, pH 9.6. Wells were washed with 
TBST and 100 ng of hfib reference, transgenic prepared whey or nontransgenic prepared whey 
dilutions were added to the plate and incubated for 30min at 37°C. Wells were washed with TBS/ 
Tween and 1:10,000 diluted horseradish peroxidase-conjugated raBβ it anti-hfib (Dako, 
Carpinteria, CA) was added to all wells and incubated for 30min at 37°C. Upon completion of 
incubation the wells were washed and 100 llof OPD (O-phenylenediamine; ABβ ott Labs, ABβ 
ott Park, IL) solution was added to each well. The reaction was stopped after 3–4 min by the 
addition of 100 llof3N H2SO4 and the absorbance was measured at 490 nm. 
 
2.7 Partial purification of the transgenic fibrinogen  
A whey pool sample was prepared from mouse milk collected from different trigenic 
fibrinogen mice. Frozen EDTA-treated prepared whey samples (derived as described above) were 
defrosted at 10oC and mixed in a vortex mixer to help resolubilize cryoprecipitated fibrinogen. 
Three ml of each prepared whey pool was applied to a 2 ml Fast-flow DEAE-Sepharose 
chromatography column, the column was then washed with 125 mM NaCl, 50 mM Tris and 200 
mM EDTA, pH 8.5 buffer, and then eluted with 250 mM NaCl, 50 mM Tris and 200 mM EDTA, 
pH 8.5 buffer. The column eluate was concentrated to 0.5 ml by lyophilization and rendered with 
8 mM zinc acetate, pH 7. The mixture was centrifuged at 10,000 x g for 3 min at room 
temperature and the supernatant and pellets were evaluated by SDS-PAGE and Western Blot 
analysis. Both the supernatant and pellets of the control mouse and transgenic whey purification 
products were retained for clotting analysis. Pellets were reconstituted in 50 mM Tris, 100 mM 
CaCl, pH 8.5 buffer at room temperature.  
 
2.8 Functional activity of transgenic fibrinogen  
The clotting activity of reference and purification products derived from control whey and 
transgenic samples was evaluated by the visual formation of a clot precipitate by the addition of 
200 U/ml bovine thrombin. Reference treatment samples consisting of 300 μg/ml hfib (gift of the 
American Red Cross) dissolved in 50 mM Tris, 100 mM CaCl, 7 and 8 mM zinc acetate, pH 8.5 
buffer. A similarly treated control whey superna- tant product was also evaluated. The thrombin 
reaction mixtures were allowed to incubate for 15 min at 21°C. All samples were centrifuged for 
2 min at 10,000  x g and examined for a clot. The samples containing evidence of a clot 
precipitate were then resuspended and adjusted to 200 μg/ml Factor XIII derived  from human 
plasma(gift of the American Red Cross).The samples were again incubated for 15 min at 21C and 
then centrifuged at 10,000 x g and then treated with 10 M Urea, 1% sodium dodecyl sulfate, 1% 
mercaptoethanol by gentle heating for 2 min at 100 °C in a capped 1 ml Eppendorf tube. The 
dissolved clot–pellet solutions were evaluated by SDS-PAGE and Western analysis using 
polyclonal anti-era against hfib γ-chain. 
 
3.0 Results: 
3.1 Expression of individual fibrinogen chains by the transgenic mammary gland. 
Individual lines of transgenic  mice were established by out breeding founder animals that 
carried  one  of the mammary specific expression vectors WAP6FibAα1  WAP6FibBβ1 or 
WAP6Fibγ1.Production efficiencies are summarized  in Table 1 for each individual construct 
where transgene integration  and transmission fell in the typical  range  for  transgenic mouse 
production. Upon  establishing lines for each construct Southern analysis was performed to judge 
transmissible  copy numbers for each line,where total transgene copies varied from 1 to greater 
than 50 among  the different lines  (Table 2).Evaluation of individual fibrinogen chain expression 
was conducted  on prepared whey from naturally lactating  females (minimum n=3) of a given 
line during  the course of lactation (days 5,10 ,15) and over successive lactations.Prepared whey 
samples were subjected to Western analysis under reducing  conditions and compared hfib 
standards. 
Only one line (43) of the generated WAP6FibAα1 mice produced a sufficient  quantity  of  Aα-
chain under non-reducing conditions that migrated identical to  human standard(Figure 
2a),suggesting this chain is properly  processed and secreted in monomer form by memmary 
ephithelia. In contrast  to the Aα-chain and Bβ  chain was  not secreted in monomer form by 
WAP6FibBβ1 mice and no chain  complexes were detected under non reducing  conditions using 
several  different antibodies .However ,secreted Bβ-chain was detected under reducing conditions 
with mobility similar to hfib(figure 2b) in three of the six established  lines. The Presence of this  
band only under reducing conditions indicates that Bβ-chain is either  secreted in association with 
other proteins or secreted in a conformation that prevents epitope  recognition  by variety of 
antibodies .Western analysis  of milk from WAP6Fibγ1 transgenic  mice under reducing 
conditions produced a band which migrated  identically to human standard (figure 2c ),suggesting 
the γ-chain was able to be secreted into milk by the  mammary epithelia of these  animals. These 
animals represented one of the two established lines. 
3.2 Expression of rhfib and chain complexes by the transgenic animal mammary gland. 
Transgenic mice carrying all three fibrinogen chain constructs were produced by co-
microinjection of individual construct at an equal molar concentration. Overall nine triple 
transgenic(WAP6FibT.C.) founder mice were generated  and upon breeding  with control  
animals ,six  lines of transgenic mice wee established. Since the three constructs were not 
physically linked before  microinjection the  transgene locus for  a given  line may vary in 
composition by the ratio and copy numbers of the gene constructs within the locus .Southern 
analysis of each  established line was performed to verify  PCR results and to quantify  the 
number of transgenes  within the integration site.The four bands produced by Sothern analysis of 
a transgenic  mouse DNA are indicated in figure 1.The fragment produced by the endogenous 
WAP genes (~50 kbps) acts as amount of DNA loaded for gel electrophoresis,due to the presence  
of endogenous WAP at  two  copies per  diploid genome (GeneBank ,NIH).By comparing  the 
signal intensities for a given lane the relative copy numbers of each transgene  within the 
integration site  were determined  and presented in table 3.Variations of both the  molecular  ratio  
of  transgenes and number of copies  present within the given locus were observed similar to that 
previously reported when using three separate transgenes (Punkard etal.,1996)  
 
Prepared milk samples from several animals of a given line over the course of first and 
second lactation were subjected to ELISA to determine which lines were expressing rhfib, to 
what level, and if expression was stable during the course of lactation. ELISA results identified 
that three of the six trigenic lines secreted detectable amounts of rhfib and/or rhfib chain 
complexes into their milk (Table 3). Upon analysis of these lines over the course of lactation, 
variations in expression were observed. Previous research has indicated that murine WAP-based 
transgenes are influenced by chromosomal DNA elements flanking the integration site by 
modulating the hormonal response of the promoter elements (Burdon et al., 1991). In order to 
verify that the lack of secreted individual chain and chain complexes is not due to the processing 
activity of mammary epithelia, but instead due to promoter activity, we conducted Northern 
analysis and have found a direct correlation between absence of mRNA and absence of protein. 
Samples with the strongest ELISA signals were subjected to Western analysis in order to 
determine if each chain was correctly processed and to identify the secretion products composing 
the signal.  
 
 
Prepared whey samples from the three expressing lines were subjected to Western 
analysis under reducing conditions using a polyclonal 3 chain antibody (Figure 3b). All three 
chains were detected in transgenic prepared whey with the migration of the rhfib Aαand Bβ  
chains being identical to human standard (lane 1), but the γ-chain  having a slightly faster 
mobility. Also present are several higher molecular weight species which most likely represent 
incomplete reduction and separation of fibrinogen and/or fibrinogen chain complexes, as these 
are not found in non-transgenic prepared whey. In order to identify the degree of secreted subunit 
assembly, identical samples were run under non-reducing conditions and probed with the same 
ADI antibody, (Figure 3a). The antibody recognizes only a single band in the human standard 
(lane 1), but also binds to mouse fibrinogen with a low affinity in lane 2. Trigenic milk samples 
have several bands present, indicating secretion of individual chains and/or chain complexes. 
There are two prominent bands (Aαand AG) with apparent sizes of 66 and 135–150 kDa, 
respectively, which correspond in molecular weight to Aachain monomers and an Aac2chain 
complex. The monomer form is found secreted in all lines studied, suggesting its ability for free 
secretion similar to monogenic a-chain mice. The Aαmonomer signal produced by prepared whey 
from line 10 is more intense than that produced by milk from mice of line 37 and 21, but in 
contrast, band AG is very weak in line 10 and very strong in the other two lines. It is important to 
note the trans-gene ratio with this line where the a transgene ratio is higher than the other two 
lines. Upon mRNA analysis by Northern a higher ratio of a message was observed in line 10 as 
compared to the other lines, confirming the behavior of the integration site to be copy number 
dependent as seen with other mWAP driven transgenes (Burdon et al., 1991). These observations 
along with the absences of bands below 198 kDa in the non-transgenic whey sample indicate 
individual chains and partial chain complexes can be secreted by the mammary gland. The other 
minor bands  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Western analysis of prepared whey from triple transgenic mice under reduced and non-
reduced conditions. Upper panel, prepared whey from triple transgenic mice was separated by SDS-PAGE 
under non-reducing (a) or reducing conditions (b) and probed with the ADI polyclonal antibody. Lane 1, 
hfib 120 ng; lane 2, 1 ll of non-transgenic prepared whey; lane 3, 1 ll of line 37 prepared whey; lane 4, 1 ll 
of prepared whey from line 37 homozygous animal; lane 5, 1 ll of line 21 prepared whey; and lane 6, 1 ll of 
line 10 prepared whey. Lower panel, prepared whey from triple transgenic mice was separated by SDS-
PAGE under non-reducing conditions and probed by a chain specific antibody; Y18, Shainoff, NC15 for 
Aa,Bβ  and°Cchains, respectively. Lane 1, 200 ng hfib; lane 2, 1 ll of non-transgenic prepared whey; lane 3, 
1 ll of line 10 prepared whey; lane 4, 1 ll of line 21 prepared whey; and lane 5, 1 ll of line 37 prepared 
whey. Band designations are: A, fibrinogen Aa-chain; AG, Aα°Ccomplex; mIg, mouse 
               c immunoglobulin; and fib, assembled fibrinogen.  
present in the transgenic milk samples may be the association of free chains or chain complexes 
with naturally occurring milk proteins such as the a caseins which are known to interact among 
themselves via cystine bridging.  
In order to identify whether the A band is free Aa-chain and the AG band contains the 
Aasubunit, a non-reduced blot from trigenic lines was probed with a Aa-chain-specific 
monoclonal antibody (Figure 3, lower panel). There are four major bands identified: Aα at~ 66 
kDa, AG at ~130–150 kDa, mIg at 180 kDa and fib ~340 kDa. The concentration of the Aαband 
is found most abundantly in the line 10 sample with lower levels found in samples from lines 21 
and 37. In contrast, the AG band was found most intense in milk samples from line 21 and 37. 
These observations indicate that free Aαhain is readily secreted by the mammary gland and a 
higher molecular weight complex containing at least the Aα-subunit is also secreted under 
conditions when all three chains are present. The mIg band produced in all mouse samples was 
due to recognition of secreted IgG by the secondary conjugated antibody (A4416, anti-mouse) 
used during blot development.  
To evaluate whether Bβ -chain was being secreted by these mice as free chain or as a 
complex, a blot using a monoclonal Bβ -subunit antibody was performed and is shown in Figure 
3, lower panel. Only two significant bands were identified, the mIg band previous discussed and 
the rhfib band migrating identically to the human standard. These observations indicate that the 
β-chain  is being produced at a level where it is incorporated into fully assembled rhfib. Since this 
antibody does not crossreact with mouse fibrinogen, the relative amounts of rhfib secreted among 
different mice can be observed. To follow the pattern of secretion for the γ-chain  and to rule out 
the possibility that the AG band was not an oligomer of Aa-subunits, a c-subunit blot was 
performed using a γ-chain  specific polyclonal antibody (Figure 3, lower panel). Two bands were 
produced: AG at 130–150 kDa and rhfib at 340 kDa. The fibrinogen band was found in all lines 
and in the human standard. The AG band was not detected in line 10 milk, but was present in 
milk samples from mice of line 21 and 37. Thus, the high molecular weight species that we have 
observed does contain all of the fibrinogen subunits.  
3.3 Glycosylation state of rhfib chains  
The glycosylation state of secreted rhfib and chain complexes was investigated in the 
highest expressing mice in order to evaluate if the mammary gland can perform necessary 
posttranslational modifications without limitation. The Aa-subunit of hfib has a punitive N-linked 
glycosylation site Asn269 and Asn400 (Rixon et al., 1983), but it is not glycosylated in fully 
assembled hfib. Deglycosylation experiments were performed to identify if Aa-subunit remains 
deglycosylated when secreted by both monogenic and trigenic mice with results presented in 
Figure 4. No band shifting was observed when human standard was digested with the enzymes 
Endoglycosidase H (high mannose, Endo-H) or Glycopeptidase (high mannose or complex, 
PNGase) that cleave N-linked saccharides. Upon treatment of trigenic prepared whey and 
monogenic prepared whey with these enzymes, shifting of the Aa-subunit was not observed. This 
suggests that the punitive site is not recognized by mammary epithelia following a similar pattern 
to that of the liver.  
The Bβ -chain of hfib is glycosylated with the carbohydrate side chain being in the 
complexed form. Glycosylation of the Bβ -subunit is not required for secretion of assembled 
fibrinogen, as cells treated with tunicamycin still can secrete fibrinogen (Yu, 1983). To evaluate 
if the secreted Bβ -subunit is glycosylated when no other fibrinogen chains are present, 
deglycosylation experiments were performed on monogenic prepared whey with results shown in 
Figure 5a. As expected, no band shifting is observed with human standard when treated with 
Endo-H, but  
 
Figure 4. Glycosylation analysis of Aa-chain from WAP6FibAαand WAP6FibT.C. mouse prepared 
whey. Prepared whey (l μl) from both monogenic and trigenic lines and hfib standard (230 ng) was 
subjected to deglycosylation with either Endoglycosidase H (Endo-H, recognizing high mannose) or 
Glycopeptidase (PNGase, cleaving both high mannose and complex structures) with resulting products run 
on SDS -PAGE and probed with the Aa-chain AB784 polyclonal antibody. Aα= fibrinogen Aα-chain, N.T. = 
non-transgenic prepared whey ( l μl).  
fibrinogen standard does shift with PNGase treatment. Some shifting of the secreted Bβ subunit is 
observed with Endo-H treatment, suggesting that some portions of the secreted Bβ  chains are of 
the high mannose type. Unfortunately, exact quantification can not be performed as the Bβ  
subunit of murine fibrinogen migrates at the same rate, but it was observed that all of the rhfib Bβ 
-subunit is glycosylated as shown by shifting of all material by PNGase. This suggests that 
mammary epithelial cells can recognize the glycosylation site of rhfib Bβ  chains when produced 
without the other fibrinogen chains and core glycosylation does occur. In this case, the processing 
ability of the mammary epithelial cell appears to be limiting, resulting in secretion of both high 
mannose and complex saccharide glycosylated Bβ  subunits. Limitations in Bβ  chain 
glycosylation are not restricted to mammary epithelia as it has been observed with transfected 
COS-1 cells that a fractional amount of Bβ  subunits in secreted rhfib was Endo-H sensitive. To 
evaluate the amount of Endo-H sensitive Bβ  subunits that are present in mammary epithelia-
derived rhfib, similar deglycosylation experiments were performed on trigenic prepared whey. 
Treatment of prepared whey derived from the  
 
Figure 5. Glycosylation analysis of Bβ -chain from WAP6Fib Bβ 1 and WAP6T.C. prepared mouse 
whey. Panel a, prepared whey ( 1 μ l) from a WAP6FiBβ b1 monogenic line and hfib standard (200 ng) was 
subjected to deglycosylation with either Endoglycosidase H (Endo-H) or Glycopeptidase (PNGase) with 
resulting products run on SDS-PAGE and probed with the Bβ -chain AB 785 polyclonal antibody. Note the 
partial shifting of the Bβ -chain produced by Endo-H digestion of monogenic whey. Panel b, prepared whey 
(1 μl) from a high expressing WAP6FibT.C. (line 37, homozygous) mouse and hfib standard (300 ng) was 
subjected to deglycosylation with Endo-H and PNGase, separation and probing with AB 785 polyclonal 
antibody. Note the majority of Bβ -chain is sensitive to Endo-H in the high expression whey. Panel c, 
prepared whey (1μ l) from a medium expressing WAP6FibT.C. (line 10) mouse which is similar in 
expression to the monogenic in panel a, and hfib standard (230 ng) was subjected to deglycosylation with 
Endo-H and PNGase, separation and probing with AB 785 polyclonal antibody. Note the lack of sensitivity 
to Endo-H in the expressed whey. N.T. ¼ non-transgenic.  
 
 
highest expressing line with Endo-H (Figure 5b) resulted in shifting of all recombinant Bβ  
chains to the deglycosylated state indicating that all assembled Bβ -chain was in the immature 
form. In contrast, when rhfib was secreted at lower levels in milk as with line 10 mice, the Bβ -
chain was not susceptible to Endo-H treatment (Figure 5c). These observations suggest a rate 
limitation for β-chain  glycosylation when it is incorporated into fully assembled fibrinogen.  
Several cell types have demonstrated the ability to N-glycosylate the°Cchains of assembled hfib 
with saccharides complex in structure. To determine the glycosylation state of the γ-chain  when 
expressed without the a-or β-chain , prepared whey from WAP6Fibc1 mice was subjected to 
deglycosylation experiments (Figure 6). Hfib standard did not shift when treated with Endo-H, 
but did show a faster mobility when treated with PNGase. Mammary epithelia derived°Cchains 
were not affected by Endo-H treatment, but did shift under PNGase treatment. This observation 
indicates that the γ-chain  can be recognized by glycosylation pathways in mammary epithelia 
when only the γ-chain  is present and does not require association with the other chains for 
glycosylation to occur. When the same experiment is performed on trigenic mouse prepared 
whey derived from line 37, a small fraction of the°Cchains became deglycosylated under Endo-H 
treatment, suggesting a subpopulation of immature°Cchains is able to be secreted. Thus, when 
total fibrinogen and fibrinogen chain complexes are secreted by mammary epithelia into milk at 
concentrations approaching 700  μg/ml, the ability of mammary epithelia to glycosylate properly 
is compromised.  
The functionality of assembled fibrinogen was assessed by first partially purifying the 
recombinant fibrinogen away from the endogenous mouse fibrinogen which typically occurs in 
milk and can be variable due to plasma passover from injury that can occur during milking. We 
adapted aZn2+-dependent solubility based purification process used for isolating proteins from 
transgenic milk (Degener et al., 1998) that discriminates between mouse and hfib (Butler et al., 
1997). After removal of the bulk of the caseins by ion exchange chromatography, the ion 
exchange eluate was rendered with ZnCl (8 mM) to precipitate mouse fibrinogen. After treatment  
 
Figure 6. Glycosylation analysis of γ-chain  from WAP6Fibc1 and WAP6T.C. prepared mouse whey. Panel a, 
prepared whey (1 μl) from a WAP6Fibc1 monogenic line and hfib standard (230 ng) was subjected to 
deglycosylation with either Endoglycosidase H (Endo-H) or Glycopeptidase (PNGase) with resulting products run 
on SDS -PAGE and probed with the Chemicon γ-chain  antibody. Note the lack of shifting under Endo-H conditions 
with the monogenic whey. Panel b, prepared whey from a WAP6FibT.C. (line 37, homozygous) mouse and hfib (230 
ng) was subjected to deglycosylation treatment by either Endoglycosidase H (Endo-H) or Glycopeptidase (PNGase) 
and separated by SDS-PAGE under reducing conditions then probed with the γ-chain  Chemicon antibody. Note the 
partial shifting of the°Cband upon Endo-H treatment of WAP6FibT.C. mouse whey. N.T. ¼ non-transgenic mouse 
whey (1 μl).  
 
with thrombin, the supernatant containing the soluble human transgenic hfib was shown to form a 
visible clot-like precipitate similar to that of the human reference sample. The clot density of the 
precipitate was found to increase after treatment with Factor XIII. No clots were formed with 
supernatants analogously derived from control mouse milk. Western analysis of these reaction 
mixtures containing human plasma derived fibrinogen (Figure 7a) and transgenic hfib (Figure 7b) 
showed the disappearance of the γ-chain  (lane 3 of panel a and panel b; human  
 
 
  
 
 
 
 
Figure 7. Functional activity of recombinant fibrinogen. Recombinant fibrinogen was purified as listed in materials 
and methods and subjected to thrombin activation and factor XIII cross linking along with human standard. 
Products were denatured then separated by SDS-PAGE followed by probing with polyclonal AB786 antibody. Panel 
a: lane 1, hfib without thrombin or factor XIII treatment; lane 2, hfib treated with thrombin; lane 3, hfib treated with 
thrombin and factor XIII. Panel b: lane 1, purified recombinant without thrombin or factor XIII; lane 2 recombinant 
with thrombin; lane 3, recombinant treated with both thrombin and factor XIII.°C°Crepresents the γ-chain –γ-
chain  crosslink.  
and transgenic hfib, respectively) and the appearance of a species at an Mr of approximately 90 
KDa after treatment with thrombin and Factor XIII. Western blot analysis specific to γ-chain  
confirmed the 90 KDa species to be a c–c crosslinked product arising from the thrombin-Factor 
XIII enzymatic reaction (data not shown). As reported previously (Prunkard et al., 1996), we 
found evidence of c-glutamyl transferase activity in the milk mixtures leading to the formation of 
c–c cross-linked chains even without the presence of human Factor XIII after thrombin treatment.  
4.0 Discussion  
The use of transgenic livestock as bioreactors to produce pharmaceutical biologics is 
maturing with several derived proteins in or about to enter clinical trials (Drohan and Clark, 
2000). New biologics are being discovered and brought forward as potential candidates for being 
produced by the transgenic mammary gland, requiring rapid evaluation of both synthesis rate and 
functionality. Transgenic mice offer this platform for evaluation due to their short generation 
intervals and ease of genetic manipulation, thus allowing production of a biologic before 
investigation in larger animals. In contrast to previous studies using immortalized cell lines, we 
have sought greater understanding of the relationship between the extent of glycosylation and 
assembly of individual chains in the context of the healthy native physiology of the transgenic 
mammary gland. Previous studies with fibrinogen secreted into the milk of transgenic mice 
(Prunkard et al., 1996) did not focus upon glycosylation or secretion limits of individual chains in 
relationship to assembly of functional mature fibrinogen.  
In this report, we established lines of transgenic mice to study the genetic stability and 
transmission characteristics of each transgene integration site and to develop both protein and 
RNA expression profiles for each unique locus. When embryos were microinjected with an equal 
molar ratio of DNA constructs, the resulting offspring had both balanced and unbalanced ratios 
incorporated into the genome. This observation is similar to a previous report (Burdon et al., 
1991) where three different transgenes consisting of slightly modified mouse WAP genomic 
sequences were co-injected resulting in highly imbalanced loci with regards to the three mouse 
lines analyzed. We performed a detailed analysis of mRNA expression for each fibrinogen gene 
in the WAP6FibT.C. loci (data not presented) and observed concert expression of each gene with 
regards to copy number within the locus and that expression of the locus varied over the course 
of lactation depending upon the line studied. This suggests that the 4.1 kbp mWAP promoter is 
heavily influenced by elements flanking the integration site similar to the 2.4 mWAP promoter 
and that the additional promoter sequences do not afford insulation from these outlying elements 
(McKnight et al., 1995). However, when the 4.1 kbp promoter is not inhibited by outlying 
repressive elements, it can drive expression of fibrinogen cDNA to sufficient levels where protein 
expression is approximately the same as when fibrinogen genomic coding elements are used such 
as with the 4.2 kbp BLG promoter (Prunkard et al., 1996). Indeed, we show here that the 4.1 kbp 
mWAP promoter can be used to independently express each fibrinogen subunit so as to result in 
the assembly of fully functionally fibrinogen capable of forming a cross-linked clot.  
While our primary goal is to evaluate the capacity of transgenic livestock as bioreactors to 
produce rhfib in milk, the mammary gland provides a novel system from which to study 
intracellular processing, assembly and secretion in a pathway which differs from most 
transformed cell lines. For example, the expression of rhfib in mammary epithelial cells of 
transgenic mice should provide a naturally less restrictive trafficking environment due to the 
nutritional role of most milk proteins. This was especially reflected by the unassembled b-rhfib 
chain as well as other partially assembled rhfib complexes which were secreted into the milk. We 
have previously shown that mammary epithelial tissue of transgenic mice can perform complex 
post-translational processing at cell synthesis rates of greater than about 1–10 pg/cell/day 
(Velander et al., 1992) and these recombinant protein synthesis rates are similar to that found in 
previous rhfib cell culture studies (Yu et al., 1984; Danishefsky et al., 1990; Hartwig & 
Danishefsky, 1991; Roy et al., 1994). Due to the high cell density of the mammary tissue relative 
to cell culture, the expression levels in milk resulting from cDNA rhfib constructs under the 
control of the 4.1 kb mWAP promoter were about 100–700  μg/ml total rhfib species. Fully 
assembled rhfib was about 200  μg/ml of the total secreted rhfib species, indicating secretory 
permissiveness in the case of assembly limitations. From this standpoint, the study of secreted 
rhfib chains and complexes is more easily done in milk than in cell culture media.  
Perhaps the biggest difference between mammary gland and cell culture expression was 
with respect to secretion of free Bβ -chain; the milk of Bβ -monogenic mice showed free Bβ -
chain, while previously no cell line has been shown to secrete Bβ -chain alone. For example, the 
secretion of immature rhfib and free hfib chains in COS-1, CHO, BHK, and HepG2 cell lines 
showed a lack of detectable, free Bβ -chain (Danishefsky et al., 1990; Roy et al., 1994). This 
occurred in both Bβ -chain only and Aa,Bβ ,γ-chain  transfected cell lines indicating a higher 
retention selectivity for Bβ -chain by the secretory pathway in these cells. Xia and Readman 
(2001) have demonstrated in HepG2 and COS cells that the intracellular levels of each fibrinogen 
chain are modulated by chain association to the degradation pathway proteins Sec61b (Bβ -chain) 
and Hsp70 (Aαand γ-chain s). Their observations coupled with those we observed with the Bβ 
chain secretion by Bβ -monogenic mice have allowed us to postulate that mammary epithelia has 
a less restrictive secretory pathway as compared to cell culture lines studied so far.  
We observed that the secretion of free β-chain  could occur at 100  μg/ml in monogenic 
mice, which is similar to the levels of the secreted free a (150  μg/ml) and°C(50  μg/ml) hfib 
chains in the respective monogenic mouse lineages. The glycosylation of the secreted free β-
chain  occurring in monogenic β-chain  mouse milk was estimated to be about 30% high mannose 
core. However, when secreted at similar levels in assembled hfib, the β-chain  contained about 
95% Endo-H sensitive carbohydrate which is similar to that found in assembled rhfib from COS-
1 cells. It is possible that the co-expression of a and c-rhfib chains with β-chain  and/or the 
assembly process occurring in trigenic mice can lower the efficiency of glycosylation processing 
of the nascent β-chain . Since there was no free β-chain  species detected in the milk of trigenic 
rhfib mice, it is unlikely that β-chain s having high mannose core were kinetically unsuitable for 
rhfib assembly.  
Free a-chain was expressed in milk at the highest levels of the monogenic lineages and 
represented as much as 10% of the total hfib species present in the milk of trigenic lineages. In 
addition, Aα–c complexes were found at significant levels in the milks of trigenic lineages and 
represented as much as about 30% of the rhfib species as detected by Western analysis. Thus, the 
trafficking leading to secretion of Aα-only and Aα- chain containing complexes including mature 
rhfib was efficient in mammary tissue and similar to other non-epithelial cell types (Danishefsky 
et al., 1990; Roy et al., 1994). In contrast to β-chain , γ-chain  was found to have no Endo-H 
sensitivity in freely secreted γ-chain  from monogenic or assembled γ-chain  in rhfib from 
trigenic lineages. Thus, in mammary epithelial cells the trafficking and γ-chain assembly into 
rhfib appears to be largely independent of glycosylation. The relative molecular weight of about 
150 kDa of the a–c containing complexes would be consistent with an a–c–c complex as has been 
postulated to occur in other cell types. Similarly to a-chain, no free γ-chain was detected in the 
milk of trigenic lineages indicating that intracellular γ-chain was not pooled in excess relative to 
the a-chain.  
In summary, we have used the less restrictive secretory pathway of the mouse mammary 
epithelia to express individual chains of a complex multimeric protein to be secreted to enable 
glycosylation patterns to be studied.  
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